RU2737291C2 - Фармацевтические составы пегилированных липосом и факторов свертывания крови - Google Patents

Фармацевтические составы пегилированных липосом и факторов свертывания крови Download PDF

Info

Publication number
RU2737291C2
RU2737291C2 RU2017115831A RU2017115831A RU2737291C2 RU 2737291 C2 RU2737291 C2 RU 2737291C2 RU 2017115831 A RU2017115831 A RU 2017115831A RU 2017115831 A RU2017115831 A RU 2017115831A RU 2737291 C2 RU2737291 C2 RU 2737291C2
Authority
RU
Russia
Prior art keywords
use according
leu
ser
gly
factor
Prior art date
Application number
RU2017115831A
Other languages
English (en)
Russian (ru)
Other versions
RU2017115831A3 (cg-RX-API-DMAC10.html
RU2017115831A (ru
Inventor
Уильям ГЕНРИ
Original Assignee
Кантаб Биофармасьютикалз Пэтентс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кантаб Биофармасьютикалз Пэтентс Лимитед filed Critical Кантаб Биофармасьютикалз Пэтентс Лимитед
Publication of RU2017115831A publication Critical patent/RU2017115831A/ru
Publication of RU2017115831A3 publication Critical patent/RU2017115831A3/ru
Application granted granted Critical
Publication of RU2737291C2 publication Critical patent/RU2737291C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
RU2017115831A 2014-10-06 2015-10-06 Фармацевтические составы пегилированных липосом и факторов свертывания крови RU2737291C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1417589.7 2014-10-06
GBGB1417589.7A GB201417589D0 (en) 2014-10-06 2014-10-06 Pharmaceutical Formulations
PCT/EP2015/073003 WO2016055447A1 (en) 2014-10-06 2015-10-06 Pharmaceutical formulations of pegylated liposomes and blood coagulation factors

Publications (3)

Publication Number Publication Date
RU2017115831A RU2017115831A (ru) 2018-11-14
RU2017115831A3 RU2017115831A3 (cg-RX-API-DMAC10.html) 2019-05-06
RU2737291C2 true RU2737291C2 (ru) 2020-11-26

Family

ID=51946871

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017115831A RU2737291C2 (ru) 2014-10-06 2015-10-06 Фармацевтические составы пегилированных липосом и факторов свертывания крови

Country Status (17)

Country Link
US (2) US20170304203A1 (cg-RX-API-DMAC10.html)
EP (1) EP3204034B9 (cg-RX-API-DMAC10.html)
JP (3) JP2017531659A (cg-RX-API-DMAC10.html)
AU (1) AU2015330102B2 (cg-RX-API-DMAC10.html)
BR (1) BR112017007031A2 (cg-RX-API-DMAC10.html)
CA (1) CA2994891C (cg-RX-API-DMAC10.html)
CY (1) CY1126253T1 (cg-RX-API-DMAC10.html)
ES (1) ES2954134T3 (cg-RX-API-DMAC10.html)
GB (1) GB201417589D0 (cg-RX-API-DMAC10.html)
HR (1) HRP20230985T1 (cg-RX-API-DMAC10.html)
HU (1) HUE063656T2 (cg-RX-API-DMAC10.html)
MX (1) MX384517B (cg-RX-API-DMAC10.html)
PL (1) PL3204034T3 (cg-RX-API-DMAC10.html)
RS (1) RS64461B1 (cg-RX-API-DMAC10.html)
RU (1) RU2737291C2 (cg-RX-API-DMAC10.html)
SM (1) SMT202300271T1 (cg-RX-API-DMAC10.html)
WO (1) WO2016055447A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201417589D0 (en) * 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
WO2017204896A1 (en) * 2016-05-26 2017-11-30 Becton, Dickinson And Company Methods and devices for liposome preparation by centrifugation
GB202111757D0 (en) * 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles for use in the treatment of haemophilia A

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004091723A1 (en) * 2003-04-15 2004-10-28 Opperbas Holding B.V. Pharmaceutical composition comprising proteins and/or polypeptides and colloidal particles
WO2007002886A2 (en) * 2005-06-29 2007-01-04 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic pr0tein-lip1d complexes

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US6326353B1 (en) 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
AU7384994A (en) 1993-08-06 1995-02-28 Opperbas Holding B.V. A method for high loading of vesicles with biopolymeric substances
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US6156337A (en) * 1994-07-08 2000-12-05 Opperbas Holding B.V. Method for high loading of vesicles with biopolymeric substances
US6310183B1 (en) * 1997-09-10 2001-10-30 Novo Nordisk A/S Coagulation factor VIIa composition
CA2329768C (en) * 1998-04-27 2008-06-10 Opperbas Holding B.V. Pharmaceutical composition comprising factor viii and neutral liposomes
PT1198490E (pt) * 1999-07-14 2006-06-30 Alza Corp Lipopolimeros neutros e composicoes liposomais que contem os mesmos
JP5090605B2 (ja) * 2000-05-03 2012-12-05 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 凝固因子viiの皮下投与
US20030232075A1 (en) 2002-05-06 2003-12-18 University Of Minnesota, A Minnesota Corporation Compositions for producing factor Xa
JP5558106B2 (ja) * 2007-01-03 2014-07-23 ノボ ノルディスク ヘルス ケア アーゲー 凝固第vii因子関連ポリペプチドの皮下投与
US20090117087A1 (en) 2007-04-13 2009-05-07 Wake Forest University Methods and compositions for printing biologically compatible nanotube composites of autologous tissue
JP2012528846A (ja) 2009-06-03 2012-11-15 マヨ、ジョン、チャールズ 深部組織の痛みを治療するための製剤
GB2486371A (en) 2009-08-21 2012-06-13 Targeted Delivery Technologies Ltd Vesicular formulations
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
AR082803A1 (es) * 2010-09-01 2013-01-09 Portola Pharm Inc Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p
HK1200695A1 (en) * 2012-04-16 2015-08-14 Cantab Biopharmaceuticals Patents Limited Optimised subcutaneous therapeutic agents
GB201417589D0 (en) * 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004091723A1 (en) * 2003-04-15 2004-10-28 Opperbas Holding B.V. Pharmaceutical composition comprising proteins and/or polypeptides and colloidal particles
WO2007002886A2 (en) * 2005-06-29 2007-01-04 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic pr0tein-lip1d complexes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BARU M. ET AL., Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy, Thrombosis and haemostasis, schattauer gmbh, (20050601), vol. 93, N6, pages 1061-1068. PENG A. ET AL., PEGylation of a Factor VIII-Phosphatidylinositol Complex: Pharmacokinetics and Immunogenicity in Hemophilia A Mice, AAPS Journal, American association of pharmaceutical scientists, (20111216), vol. 14, N1, doi:10.1208/S12248-011-9309-2, pages 35-42. *

Also Published As

Publication number Publication date
GB201417589D0 (en) 2014-11-19
MX2017004378A (es) 2018-02-09
US20190060235A1 (en) 2019-02-28
HUE063656T2 (hu) 2024-01-28
JP7573582B2 (ja) 2024-10-25
CY1126253T1 (el) 2026-02-25
PL3204034T3 (pl) 2023-11-06
CA2994891A1 (en) 2016-04-14
JP2017531659A (ja) 2017-10-26
BR112017007031A2 (pt) 2018-01-30
JP2023002687A (ja) 2023-01-10
CA2994891C (en) 2023-04-04
EP3204034A1 (en) 2017-08-16
RU2017115831A3 (cg-RX-API-DMAC10.html) 2019-05-06
RU2017115831A (ru) 2018-11-14
EP3204034C0 (en) 2023-06-07
RS64461B1 (sr) 2023-09-29
US20170304203A1 (en) 2017-10-26
AU2015330102A1 (en) 2017-05-25
US11484499B2 (en) 2022-11-01
MX384517B (es) 2025-03-14
ES2954134T3 (es) 2023-11-20
AU2015330102B2 (en) 2021-01-28
EP3204034B1 (en) 2023-06-07
SMT202300271T1 (it) 2023-09-06
EP3204034B9 (en) 2023-10-04
JP2020183446A (ja) 2020-11-12
WO2016055447A1 (en) 2016-04-14
HRP20230985T1 (hr) 2023-12-08

Similar Documents

Publication Publication Date Title
JP7573582B2 (ja) Peg化リポソームおよび血液凝固因子の製剤処方
US20240366732A1 (en) Modified colloidal particles for use in the treatment of haemophilia a
US20250170244A1 (en) Colloidal particles for use in medicine
WO2017064289A1 (en) Colloidal particles for topical administration with therapeutic agent
WO2017064300A1 (en) Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
US20240358801A1 (en) Modified colloidal particles for use in the treatment of haemophilia a
US20250064738A1 (en) Modified colloidal particles for use in the treatment of haemophilia a